Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad-EM2
- Development stage
- Preclinical
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intrathecal
01
Overview
Ad-EM2 is an experimental gene therapy consisting of an adenovirus vector carrying an engineered gene for endomorphin-2 (EM2). EM2 is an endogenous opioid peptide with high affinity and selectivity for the mu-opioid receptor. The construct includes a signal peptide from mouse growth factor to facilitate the secretory expression of EM2. By delivering this gene directly to the central nervous system, Ad-EM2 provides sustained release of EM2 into the cerebrospinal fluid, which has been shown in preclinical models to alleviate symptoms of opioid withdrawal syndrome. This approach aims to overcome the short half-life of EM2 peptides, offering a potential novel therapeutic for managing opioid dependence.
- Other names
- Ad-EM-2Ad-EM2Ad-EM 2adenovirus-mediated endomorphin-2
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on Ad-EM2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad-EM2.